Everything below concerns incretin. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-02-07. Numbers and descriptions here follow the published literature rather than marketing material.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Includes the 39-residue backbone and the attached fatty diacid |
| Molecular weight | Approximately 4813 Da | Average mass; the monoisotopic value is slightly lower |
| Receptor targets | GIP receptor and GLP-1 receptor | Dual engagement defines the pharmacological class |
| Backbone length | 39 amino acids | Sequence modified from native glucose-dependent insulinotropic polypeptide |
| Albumin interaction | Reversible, mediated by the fatty diacid | Slows renal clearance and lengthens circulation time |
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.
Purified material is typically handled as a lyophilized powder kept at or below minus twenty degrees Celsius, shielded from light and moisture. In that state the solid remains stable for extended periods, although repeated freeze-thaw cycling can encourage aggregation. Once dissolved, aqueous solutions are less durable and are generally held cold and used within a brief window. Buffer composition, pH and ionic strength all influence degradation rates, and mildly acidic to neutral conditions are commonly examined. Actual shelf life depends on formulation, concentration and container, so stability limits are established experimentally rather than assumed.
== Ubiquitous function == This enzyme can catalyse the conversion of many alternative substrates, including alcohols such as retinol, which it converts to retinal. It also has an important role in the metabolism of nitric oxide, which is reactive and often found in tissue in the form of S-nitrosoglutathione (GSNO), its adduct with glutathione (GSH). The enzyme is a class III alcohol dehydrogenase (ADH) encoded by the ADH5 gene in humans and can act as a S-nitrosoglutathione reductase (GSNOR). It is a primordial ADH that is ubiquitously expressed in plant and animals alike. GSNOR reduces GSNO to the unstable intermediate, S-hydroxylaminoglutathione, which then rearranges to form glutathione sulfinamide, or in the presence of excess GSH, forms glutathione disulfide and hydroxylamine.
== Early life and biography == Kearon was born on 18 July 1961 in Carlisle, England. He spent part of his youth in Saudi Arabia, where his father worked. After his father's death when Kearon was 19, he gave up on additional formal education and entered the workforce. His first job was working for a Member of Parliament, and he later worked for Nestlé in England, Saudi Arabia, and the United States. He owned his own public affairs consulting company before beginning his full-time service in the church. Kearon was first introduced to the church in the mid-1980s while staying with a Latter-day Saint family in Laguna, California. He has said that the family "lived a joyful existence founded on service." He met missionaries in London several years later and began learning about the church, and was baptized on Christmas Eve, 1987.
=== Culinary concerns === Jalapeños are a low-acid food with a pH of 4.8–6.0 depending on maturity and individual pepper. If canned or pickled jalapeños appear gassy, mushy, moldy, or have a disagreeable odor, then to avoid botulism, special precautions are needed to avoid illness and spread of the bacteria. Canning or packaging in calcium chloride increases the firmness of the peppers and the calcium content, whether or not the peppers are pickled as well as canned. In 2008, fresh jalapeños from Mexico were tested positive for Salmonella leading the FDA to believe that the peppers were responsible for much of the 2008 United States salmonellosis outbreak. This large outbreak of Salmonella led to increased research into the detection of pathogens on jalapeños, the frequency and behavior of foodborne illness related to jalapeños, and ways to prevent foodborne illnesses from fresh jalapeños. Contaminated irrigation water and processing water are the two most common methods by which jalapeños become contaminated, as was the case in the 2008 outbreak. Jalapeños have similar microbial properties to tomatoes. The outer layer of their skin provides a safe environment for pathogens to survive, and if damaged or chopped provides a growth medium for these pathogens. Washing fresh jalapeños is important to reduce pathogen counts both at the farm and consumer level, but without cold storage it is insufficient to prevent pathogen spread.
Sources: en.wikipedia.org
In his 1970 paper "Spinal Perineurial and Meningeal Cysts", Tarlov described the clinical features, diagnosis, and classification of spinal perineurial cysts, and distinguished them from other spinal cysts such as meningeal diverticula and intradural arachnoid cysts, which had often been conflated in earlier literature. He emphasized the importance of distinguishing these lesions to avoid unnecessary surgical interventions and diagnostic errors. Tarlov reported that perineurial cysts contained nerve root fibers and typically did not fill with contrast dye (Pantopaque) during initial myelography, although delayed filling may have been evident days or weeks later due to limited communication with the subarachnoid space. In contrast, meningeal diverticula do not contain nerve fibers, have free communication with the subarachnoid space, and usually fill immediately with contrast dye during myelography.
=== Serotonin === Similarly, after some research suggested that drugs that block the recycling, or reuptake, of serotonin seemed to help some people diagnosed with depression, it was theorized that people with depression might have lower-than-normal serotonin levels. Though widely popularized, this theory was not borne out in subsequent research. Therefore, selective serotonin reuptake inhibitors (SSRIs) are used to increase the amounts of serotonin in synapses.
In plants, algae, cyanobacteria, and phototrophic and chemoautotrophic Pseudomonadota (formerly referred to as proteobacteria), the enzyme usually consists of two types of protein subunit, called the large chain (L, about 55,000 Da) and the small chain (S, about 13,000 Da). The large-chain gene (rbcL) is encoded by the chloroplast DNA in plants. There are typically several related small-chain genes in the nucleus of plant cells, and the small chains are imported to the stromal compartment of chloroplasts from the cytosol by crossing the outer chloroplast membrane. The enzymatically active substrate (ribulose 1,5-bisphosphate) binding sites are located in the large chains that form dimers in which amino acids from each large chain contribute to the binding sites. A total of eight large chains (= four dimers) and eight small chains assemble into a larger complex of about 540,000 Da. In some Pseudomonadota and dinoflagellates, enzymes consisting of only large subunits have been found. Magnesium ions (Mg2+) are needed for enzymatic activity. Correct positioning of Mg2+ in the active site of the enzyme involves addition of an "activating" carbon dioxide molecule (CO2) to a lysine in the active site (forming a carbamate). Mg2+ operates by driving deprotonation of the Lys210 residue, causing the Lys residue to rotate by 120 degrees to the trans conformer, decreasing the distance between the nitrogen of Lys and the carbon of CO2. The close proximity allows for the formation of a covalent bond, resulting in the carbamate.
Sources: en.wikipedia.org
"Sometimes Always", taken from Stoned & Dethroned, became the band's most commercially successful single in the US as it peaked at No. 96 on the Billboard Hot 100. The band departed from WEA after ten years, and then signed with Sub Pop Records in the US and re-signed with Creation Records in the UK for the release of the album Munki in 1998. The band broke up the following year as a result of an onstage altercation the year prior; William Reid prematurely left a tour after fighting with an intoxicated Jim Reid. They eventually reunited in 2007, and in 2017, they released Damage and Joy, their first studio album in 19 years and seventh overall. Their next album, Glasgow Eyes, was released in 2024 and became the band's first top 10 album in the UK since 1988.
=== Elsewhere === Generally, the firmer styles of tofu are used for kebabs, mock meats, and dishes requiring a consistency that holds together, while the softer styles can be used for desserts, soups, shakes, and sauces. Some people enjoy tofu made and prepared with chocolate and making it into pies and mousse along with other tofu desserts. This came about due to vegans and vegetarians avoiding the usage of items such as milk and eggs. Firm Western tofu types can be barbecued since they hold together on a barbecue grill. These types are usually marinated overnight as the marinade does not easily penetrate the entire block of tofu. (Techniques to increase the penetration of marinades include stabbing repeatedly with a fork or pressing out the initial water content either by hand or with a tofu press prior to marinating. Before pressing the tofu, it is sometimes frozen and thawed in order of creating a more porous texture, often compared to a sponge. This texture does not only help release the initial water content, but also allows for an altered mouthfeel and more absorbent structure. Typically, the tofu is frozen and thawed once, although some culinary experts recommend executing this technique twice for a stronger effect.) Grated firm Western tofu is sometimes used in conjunction with textured vegetable protein (TVP) as a meat substitute. Softer tofus are sometimes used as a dairy-free or low-calorie filler. Silken tofu may be used to replace cheese in certain dishes, such as lasagna.
From the 22 individual events, a total of 12 riders won races while the World Tour lead changed five times between van Vleuten, Vos and Marta Bastianelli (Team Virtu Cycling). With 46 points, Wiebes was the winner of the youth classification for riders under the age of 23. Wiebes took seven victories during the season including three consecutive races at the Prudential RideLondon Classique, the Postnord UCI WWT Vårgårda West Sweden race and the Ladies Tour of Norway. Second place went to Valcar–Cylance rider Marta Cavalli with 42 points, who won four races during the 2019 season. In the World Tour's other classification, the teams classification, Boels–Dolmans made it four consecutive titles with a total of 4045 points; three of their riders – Anna van der Breggen (three wins), Amy Pieters and Christine Majerus (one win) – all finished inside the top-ten of the individual standings. They finished well clear of second-place Team Sunweb on 2946 points – who failed to take an overall victory – and the new-for-2019 Trek–Segafredo team, who took three victories, finished third with 2547.98 points.
Sources: en.wikipedia.org
It is a synthetic peptide that activates both the GIP and GLP-1 receptors, making it a dual agonist. Approved products are given by injection rather than by mouth. It is not a small molecule and does not belong to the older sulfonylurea or thiazolidinedione families.
Engaging two receptors recruits signaling pathways that only partly coincide. This can shift the magnitude of effects on insulin release, glucagon levels and appetite relative to selective agents. Whether the pairing delivers benefits beyond a simple sum of the two is still debated in the literature.
The proportional contribution of each receptor to observed clinical effects has not been fully separated. Long-term consequences of continuous dual stimulation are likewise unclear. Investigators continue to probe these points through laboratory and clinical work.
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.